News

STALICLA réinvente le traitement de l’autisme

Pour la sixième année consecutive Bilan a dévoilé le 1er mars dernier (en exclusivité pour les lecteurs du magazine) sa selection de 50 start-up suisses pour investir ou s’inspirer. Avec 141 start-up présélectionnées par la rédaction de Bilan et nos partenaires ( BioAlps, CleantechAlps, AlpICT, la FONGIT et CIMARK, InnoSuisse, InnoVaud, MassChallenge, Neode, Kickstart Accelerator ainsi que Startupticker), le cru 2018 aboutit à un renouvellement à 98% des jeunes pousses choisies par le jury (voir sa composition ci-dessous). Place donc à la découverte et à la qualité.

Read more

Lynn Durham to join panel at Neurotech Conference in Boston, USA

STALICLA SA’s CEO Lynn Durham will be part of the panel at the Neurotech Investing & Partnering Conference taking place on May 1st in Boston, USA. The ‘Targeting Orphan Diseases’ panel which Lynn is a part of, will take place at 3:40pm Tuesday May 1st.

Read more

Lynn Durham to present at SACHS Biocapital USA Forum in NY

SACHS Biocapital USA Forum taking place on 21st March at the New York Academy of Sciences, USA. We are delighted to announce that CEO Lynn Durham will deliver a presentation showcasing STALICLA’s innovative approach and development pipeline, at 11:20am. In addition, Lynn will also be a part of the of the ‘Renewed Approaches for Neuroscience’ panel, which will be held at 11:45am. The Plenary panel is likely to be a highly anticipated session where Lynn will be discussing the hot topic of advanced therapeutics alongside other biotech and pharmaceutical leaders.

Read more

Search for content on Stalicla...